5th Nasal Formulation and Delivery Summit

Navigate Drug-Device Compatibility, Predictive Clinical Translation, CMC, Regulatory Pathways for Combination Products, and Investment Strategy to Advance Best in Class Intranasal Delivery

Intranasal delivery is at a tipping point. The first approved nose-to-brain therapy has validated the approach, while easier administration, delivery efficiency, and lifecycle management opportunities are driving investment across multiple therapeutic areas. With a growing wave of innovative biotechs reporting promising clinical results and the industry anticipating its next landmark approval, intranasal drug delivery has never offered greater opportunity or excitement.

The 5th Nasal Formulation and Delivery Summit is uniting leading biotechs, pharma, and investors to optimize drug and device compatibility, overcome challenges in formulation, and navigate commercial strategy and investment to optimize efficient drug delivery.

From optimizing nose-to-brain delivery and improving bioavailability to navigating challenging funding opportunities, join 70+ CEOs, CSOs, and Heads of R and D, Formulation, and CMC to advance intranasal treatment for CNS, emergency-use, neurological, and infectious diseases for unparalleled patient efficacy.

URLs:
Website: https://go.evvnt.com/3850271-0?pid=2874
Brochure: https://go.evvnt.com/3850271-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Drug Developer Pricing - Conference + 2 Workshops: USD 4507.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3828.00,
Drug Developer Pricing - Conference Only: USD 3149.00,
Academic Pricing - Conference + 2 Workshops: USD 3907.00,
Academic Pricing - Conference + 1 Workshop: USD 3328.00,
Academic Pricing - Conference Only: USD 2749.00,
Service Provider Pricing - Conference + 2 Workshops: USD 5397.00,
Service Provider Pricing - Conference + 1 Workshop: USD 4698.00,
Service Provider Pricing - Conference Only: USD 3999.00

Speakers: Olivier Kitten, Founder and Chief Executive Officer, Affilogic, Heather Loring, Associate Director - Search and Evaluation, AstraZeneca, Brian Taubenheim, Chief Operations Officer, Belhaven Biopharma, Tracy Brandmeyer, Co-Founder and Chief Executive Officer, Cognigenics, Paul Radspinner, President and Chief Executive Officer, Flugen, Robin Guo, Chief Executive Officer, Lionbio, Stephen Shrewsbury, Fractional Chief Medical Officer, Lionbio and TransformBio, Gavin Gear, Chief Executive Officer and Owner, LOGIX BIOSCIENCES, Sefi Rosenfeld, Director - Pre-clinical and Early Clinical Development, Nasus Pharma, Stuart Madden, Chief Scientific Officer, Neurelis, Larry Brown, Chief Scientific Officer, Noveome Biotherapeutics, Jason Cook, Co-founder and Chief Executive Officer, Olfax Medical, Parnian Lak, Founder and Chief Executive Officer, Olfera, James Kelly, Chief Medical Officer, Oragenics, Robert Ronn, Senior Vice President and Head, Research and Development, Orexo, Susan Conroy, Chief Executive Officer, Therakind, Zachary Warnken, Director, Pharmaceutical Development, Via Therapeutics, Angel Angelov, Chief Medical Officer, Vistagen, Timothy Sullivan, Chief Executive Officer, Zeteo